article thumbnail

Wake Network Retains CRO Santé Cannabis to Conduct Clinical Trials in Psilocybin Therapies

Cannabis Law Report

Both parties to this new relationship are committed to excellence in clinical research and patient access to psychedelic medicine with a focus on naturally derived psilocybin. As two emergent complementary medicines, many parallels exist between the medical cannabis industry and the currently developing psychedelic medicine industry.

article thumbnail

Final Phase of MDMA Clinical Trials Shows Drug Is 90% Effective at Treating PTSD

SpeedWeed

A first-of-its-kind Phase 3 clinical trial has found that MDMA-assisted therapy provided meaningful relief from PTSD symptoms in nearly 90 percent of study participants. The subjects had been experiencing PTSD symptoms for an average of 14 years, and 84 percent had a history of developmental trauma. Image via.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

The history and science of psychedelics: from acid and shrooms to ketamine and salvia

The Cannigma

And while most psychedelics are currently illegal in the United States and around the world, researchers are exploring their use in medicine to treat conditions such as depression, PTSD, addiction, anxiety, OCD, migraines, end of life acceptance of mortality, and eating disorders. Now, psychedelic research is booming. Classical psychedelics

History 119
article thumbnail

New Title: Canada McGill – Queens University Press: Remedicalising Cannabis Science, Industry, and Drug Policy By Suzanne Taylor

Cannabis Law Report

A contemporary history of the remedicalization of cannabis and the shifting boundaries between licit and illicit drugs. Within a decade cannabis-based drugs were back in the clinic. The UK is one of the biggest producers of medicinal cannabis, but few patients have access to these medicines. Learn more and order.

article thumbnail

Use of Cannabis-based medicinal products: NICE guidelines

Cannabis Law Report

Cannabis-based medicinal products. Making decisions using NICE guidelines explains how we use words to show the strength (or certainty) of our recommendations, and has information about prescribing medicines (including off-label use), professional guidelines, standards and laws (including on consent and mental capacity), and safeguarding.

article thumbnail

Ketamine One Advances Research Capabilities via Controlled Substance Dealers Licence Application

Cannabis Law Report

The Company and Its Subsidiary KGK Science Have Also Completed the Pre-Qualification Audits of Its Canadian Facilities to Enable Clinical Trials in an Arrangement with Aleafia Health. The audits will enable KGK to conduct clinical trials in the areas of psychedelics and nutraceuticals, among other substances of study.

article thumbnail

And Here We Go Again! NASDAQ Article: Forget Cannabis: Psychedelic Medicine Is the Better Investing Opportunity

Cannabis Law Report

The global march toward cannabis legalization has seemingly awoken another long dormant area of scientific interest: psychedelics as medicine. In lockstep with the FDA’s more open-minded approach toward psychedelic medicine, Denver, Oakland, and Santa Cruz all decided to decriminalize magic mushrooms. Hundreds of other U.S.